No Data
No Data
Express News | Syndax Pharmaceuticals Inc: 52% Crc (14 of 27 Pts) Observed in Augment-102 Trial
Express News | Syndax Pharmaceuticals Inc: 96% Crc (23 of 24 Pts) Observed in Beat Aml Trial
Express News | Syndax Pharmaceuticals Inc: Plans to Initiate a Pivotal Trial With This Combination in Front-Line Newly Diagnosed Patients by Year-End 2024
Express News | Syndax Presents Updated Positive Data From Beat Aml and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients With Acute Leukemias at Eha 2024 Congress
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating
BofA Securities analyst Jason Zemansky maintains $Syndax Pharmaceuticals(SNDX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 67.9% and a total average return of 3
Express News | Syndax Pharmaceuticals Inc : BofA Global Research Raises Price Objective to $31 From $29